Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05278858 · ClinicalTrials.gov registry record · Phase 4

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

A Phase 4 study, sponsored by University Hospitals Cleveland Medical Center.

Terminated
Registry status
Phase 4
Development phase
3
Enrollment target

NCT05278858 is a Phase 4 study that was terminated before completion, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 3 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05278858, a Phase 4 study, was terminated before completion, sponsored by University Hospitals Cleveland Medical Center.

TERMINATED
Registry status
Phase 4
Development phase
3 participants
Enrollment target

Study Summary

This is an interventional pilot study assessing the tolerability of needle-free delivery administration of ILTA with the Med-Jet as an alternative to conventional syringe and needle in patients with patchy pediatric alopecia areata. There will be a total of four (4) or five (5) visits necessary for study participation. The investigators hypothesize that the Med-Jet will have acceptable pain tolerability, efficacy, safety, and a positive impact on patient quality of life.

Interventions

  • COMBINATION_PRODUCT MedJet Device with intralesional triamcinolone

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2022-03-24
Est. Completion 2023-06-06
Phase Phase 4

What the Registry Record Tells You About NCT05278858

The ClinicalTrials.gov registry entry for NCT05278858 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which MedJet Device with intralesional triamcinolone is the first listed.

NCT05278858 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05278858 about?

NCT05278858 is a clinical study titled "Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata". This is an interventional pilot study assessing the tolerability of needle-free delivery administration of ILTA with the Med-Jet as an alternative to conventional syringe and needle in patients with patchy pediatric alopecia areata. There will be a total of four (4) or five (5) visits necessary for ...

What is the current status of trial NCT05278858?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2022-03-24. Estimated completion is 2023-06-06.

What interventions are being tested in trial NCT05278858?

The interventions under investigation include: MedJet Device with intralesional triamcinolone (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05278858?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.